Matched cohort study on the efficacy of tocilizumab in patients with COVID-19

https://doi.org/10.1016/j.onehlt.2021.100214

The objective of this study is to analyze whether the use of tocilizumab is associated with respiratory improvement and a shorter time to discharge in patients with COVID-19 and lung involvement. There were 96 patients treated with tocilizumab. Of them, 22 patients could be matched with an equivalent number of control patients. The increment in SAFI from baseline to 48h of treatment, was not significantly different between groups (tocilizumab: -0.04; control: 0.09; p=0.636). Also, no difference in time to discharge was found between the two sub-cohorts (logrank test: p=0.472). The logistic regression models, did not show an effect of tocilizumab on mortality (OR 0.99; p=0.990). We did not find a clinical benefit associated with the use tocilizumab, in terms of respiratory function at 48h of treatment, or time to discharge.

Tags: